Information about Molnupiravir ▼
Which best describes you?
For information in another country
Based outside of the United Kingdom? Click on the link below to view information for the other countries
The MHRA has issued a Conditional Marketing Authorisation for Lagevrio (molnupiravir) in Great Britain and a temporary Regulation 174 authorisation for Northern Ireland to ensure supply across all of the UK.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://coronavirus-yellowcard.mhra.gov.uk for how to report side effects.
GB-ANV-00001 | Date of Preparation: November 2021